ArticleFrontiers in molecular biosciences2021
Pan-Cancer Analysis Identified
Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- C1ORF112 drives lung adenocarcinoma progression through e2f8-mediated transcriptional activation.Journal of thoracic disease · 2026Article
- Novel driver gene FIRRM regulates the cell cycle for promoting tumor growth in hepatocellular carcinoma.Journal of gastroenterology · 2026Article
- scDeepAPA: a deep learning framework for single-cell alternative polyadenylation identification.Briefings in bioinformatics · 2026Article
- C1orf112 promotes breast cancer growth by modulating the cell cycle.Frontiers in bioengineering and biotechnology · 2026Article
- Molecular mechanisms by which C1orf112 promotes endometrial cancer progression and the development and validation of a clinical scoring model.Clinical epigenetics · 2025Article
- Effects of Coronin 2A on prognosis and immune microenvironment in tumor patients: a knowledge map of the novel biomarker via bioinformatics analysis.Discover oncology · 2025Article
- Pan-cancer analysis reveals immunological and prognostic significance of CCT5 in human tumors.Scientific reports · 2025Article
- ZNF165: A Pan-Cancer Biomarker with Prognostic and Therapeutic Potential.Protein and peptide letters · 2025Article
- Pan-Cancer Analysis of GPR141: Unveiling its prognostic significance, immune microenvironment interactions, and therapeutic potential.Journal of Cancer · 2025Article
- Current innovations in head and neck cancer: From diagnostics to therapeutics.Oncology research · 2025Review
- Deciphering the role of LOC124905135-related non-coding RNA cluster in human cancers: A comprehensive review.Heliyon · 2024Review
- Exploring the Effect of Fidgetin-Like 1 on Colorectal Cancer Through Tissue Chip and In Vitro ExperimentsBalkan medical journal · 2024Article
- Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions.Cell death & disease · 2024Article
- FLIP(C1orf112)-FIGNL1 complex regulates RAD51 chromatin association to promote viability after replication stress.Nature communications · 2024Article
- TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis.Current molecular medicine · 2024Article
- Article
- FIRRM cooperates with FIGNL1 to promote RAD51 disassembly during DNA repair.Science advances · 2023Article
- Systematic pan-cancer analysis identifies SLC31A1 as a biomarker in multiple tumor types.BMC medical genomics · 2023Article
- Article
- Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.